Kobayashi's Georgia plant released Zim's OTC pain drugs without microbial testing and lacked quality unit oversight, FDA says.
What happened
FDA inspected Kobayashi America Manufacturing, LLC in Dalton, Georgia, from May 23 to 27, 2022, and found the firm released over-the-counter Zim's Max Freeze gel, roll-on and liquid without testing batches for microorganisms. FDA also found the quality unit (the group responsible for batch release decisions) did not review contract manufacturer records before release, and that complaint handling was inadequate. FDA judged the firm's June 21, 2022 response inadequate, and a labeling review found the ZIM'S HYDRO COOLING PAIN RELIEF PATCH is an unapproved new drug.
What FDA found
The firm released batches such as Zim's Max Freeze Roll-on lot B87695 without testing them for microorganisms, and its quality assurance director said microbial testing is not part of release testing.
21 CFR 211.165(b)The quality unit did not review or approve production and control records from its contract manufacturer before the product was released and distributed.
21 CFR 211.22Zim's Max Freeze S lot B77086 was relabeled for a different market without review and approval of its manufacturing, packaging and testing records.
21 CFR 211.22The firm did not have adequate procedures for keeping and investigating customer complaints.
21 CFR 211.22ZIM'S HYDRO COOLING PAIN RELIEF PATCH is an unapproved new drug because it does not match the allowed conditions for external analgesics: lidocaine is not permitted in a counterirritant product, and menthol at 1% is below the allowed 1.25 to 16% range.
Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The patch is also misbranded because it is a nonprescription drug that does not meet the requirements for marketing without an approved application.
Section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)
What FDA wants
FDA tells the firm to respond in writing within 15 working days describing corrective actions, including microbial specifications and retrospective testing of retained samples, a plan to strengthen the quality unit, and a batch-by-batch review of products now on the market. FDA also strongly recommends hiring a consultant to help meet CGMP requirements.
Who should pay attention
- brands that buy finished OTC drug products from contract manufacturers
- contract manufacturers and packagers making topical OTC drugs
- retailers and distributors selling Zim's branded OTC products
This is a summary. Read the original letter on fda.gov.